We are live on
!
Find out more
ED
Exane Derivatives Portfolio holdings
AUM
$174M
1-Year Est. Return
7.84%
This Fund
S&P 500
This Quarter
Est. Return
+7.67%
1 Year Est. Return
-7.84%
3 Year Est. Return
+42.72%
5 Year Est. Return
+56.28%
10 Year Est. Return
–
AUM
$441M
AUM Growth
+$91.2M
(+26%)
Cap. Flow
+$74.5M
Cap. Flow
% of AUM
16.9%
Top 10 Holdings %
Top 10 Hldgs %
24.04%
Holding
1,099
New
222
Increased
266
Reduced
262
Closed
55
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UBS Group
UBS
|
+$15.4M |
| 2 |
Stellantis
STLA
|
+$9.9M |
| 3 |
Alcon
ALC
|
+$7.77M |
| 4 |
Amazon
AMZN
|
+$6.64M |
| 5 |
Ferrari
RACE
|
+$5.26M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares MSCI Taiwan ETF
EWT
|
+$8.02M |
| 2 |
RSX
VanEck Russia ETF
RSX
|
+$6.88M |
| 3 |
Linde
LIN
|
+$5.74M |
| 4 |
iShares MSCI Saudi Arabia ETF
KSA
|
+$5.13M |
| 5 |
iShares MSCI Turkey ETF
TUR
|
+$4.56M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 15.26% |
| 2 | Technology | 13.6% |
| 3 | Financials | 12.86% |
| 4 | Healthcare | 10.91% |
| 5 | Industrials | 10.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CMA
501
DELISTED
Comerica
CMA
| $138K | 0.03% |
2,001
+959
| +92% | +$71.1K |
|
502
Nuveen Quality Municipal Income Fund
NAD
$2.72B
| $137K | 0.03% |
8,400
| – | – |
|
503
Emergent Biosolutions
EBS
$378M
| $137K | 0.03% |
2,357
-769
| -25% | -$49.4K |
|
504
Las Vegas Sands
LVS
$31.6B
| $136K | 0.03% |
2,702
+2,670
| +8,344% | +$154K |
|
505
CareDx
CDNA
$1.88B
| $136K | 0.03% |
1,635
-769
| -32% | -$61.1K |
|
506
Micron Technology
MU
$1.02T
| $135K | 0.03% |
1,726
+1,468
| +569% | +$124K |
|
|
AWF
507
AllianceBernstein Global High Income Fund
AWF
$868M
| $135K | 0.03% |
10,900
| – | – |
|
508
Zai Lab
ZLAB
$2.1B
| $134K | 0.03% |
785
+456
| +139% | +$73.4K |
|
509
Itron
ITRI
$3.76B
| $133K | 0.03% |
1,371
-2,951
| -68% | -$274K |
|
510
uniQure
QURE
$2.63B
| $133K | 0.03% |
4,775
+825
| +21% | +$27.6K |
|
511
Kiniksa Pharmaceuticals
KNSA
$4.89B
| $131K | 0.03% |
9,505
+2,941
| +45% | +$44.7K |
|
|
GTHX
512
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $130K | 0.03% |
6,741
+631
| +10% | +$14K |
|
513
Incyte
INCY
$23.7B
| $129K | 0.03% |
1,600
+651
| +69% | +$54.3K |
|
514
iShares Biotechnology ETF
IBB
$9.44B
| $125K | 0.03% |
777
| – | – |
|
|
PPLT
515
abrdn Physical Platinum Shares ETF
PPLT
$1.85B
| $123K | 0.03% |
+11,910
| New | +$132K |
|
516
Huntington Bancshares
HBAN
$34.7B
| $122K | 0.03% |
+8,613
| New | +$132K |
|
517
Rapid7
RPD
$643M
| $122K | 0.03% |
1,188
-268
| -18% | -$22.6K |
|
518
Intel
INTC
$462B
| $120K | 0.03% |
2,102
-3,182
| -60% | -$187K |
|
519
RingCentral
RNG
$4.5B
| $118K | 0.03% |
417
+126
| +43% | +$36K |
|
520
Herc Holdings
HRI
$5.34B
| $118K | 0.03% |
1,031
-186
| -15% | -$19.7K |
|
|
VMW
521
DELISTED
VMware, Inc
VMW
| $117K | 0.03% |
774
-692
| -47% | -$111K |
|
522
State Street SPDR S&P Biotech ETF
XBI
$10.2B
| $117K | 0.03% |
901
| – | – |
|
523
NetEase
NTES
$79.2B
| $116K | 0.03% |
1,037
-890
| -46% | -$98K |
|
524
FuboTV Inc
FUBO
$256M
| $116K | 0.03% |
352
+16
| +5% | +$4.57K |
|
525
Vanguard Emerging Markets Government Bond ETF
VWOB
$6.16B
| $116K | 0.03% |
1,460
-232
| -14% | -$18.3K |
|
Similar funds
PC
TWMP
LPWM
ACM
HWIS
LWM
EW
GDWAM
Exane Derivatives's Q2 2021 Portfolio in Review
As of Q2 2021, Exane Derivatives held 1,099 positions worth $441M, up 26% from $350M the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Exane Derivatives deployed $74.5M of net new capital in Q2 2021, opening 222 new positions and adding to 266 existing holdings. Its largest new stake was Alcon: 109,041 shares worth $7.62M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 15% of assets, up from 11% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was iShares MSCI Taiwan ETF, an estimated $8.02M trimmed.
- Exane Derivatives's largest Q2 2021 buy was Alcon: 109,041 shares worth $7.62M.
- Exane Derivatives added most to UBS Group in Q2 2021, an estimated $15.4M increase.
- Exane Derivatives's biggest Q2 2021 reduction was iShares MSCI Taiwan ETF, cutting an estimated $8.02M.
- Exane Derivatives fully exited Deutsche Bank in Q2 2021, selling an estimated $4.27M.
- Exane Derivatives's ten largest holdings make up 24% of its $441M portfolio in Q2 2021.
- Exane Derivatives opened 222 new positions and closed 55 in Q2 2021.
- Exane Derivatives's portfolio value rose 26% quarter-over-quarter to $441M.
Based on Exane Derivatives's 13F filing for Q2 2021, filed 28 Jul 2021.